| Literature DB >> 30638109 |
Ryosuke Numaguchi1, Masato Furuhashi2, Megumi Matsumoto2, Hiroshi Sato1, Yosuke Yanase1, Yosuke Kuroda1, Ryo Harada1, Toshiro Ito1, Yukimura Higashiura2, Masayuki Koyama2, Marenao Tanaka2, Norihito Moniwa2, Masanori Nakamura3, Hirosato Doi1,4, Tetsuji Miura2, Nobuyoshi Kawaharada1.
Abstract
Background Perivascular adipose tissue ( PVAT ) is causally associated with vascular function and the pathogenesis of vascular disease in association with metabolically driven chronic inflammation called metaflammation. However, the difference in PVAT surrounding the coronary artery ( CA - PVAT ) and that surrounding the internal thoracic artery (ITA-PVAT), a vessel resistant to atherosclerosis, remains unclear. Herein, we investigated whether CA - PVAT , ITA - PVAT , and subcutaneous adipose tissue ( SCAT ) have distinct phenotypes. Methods and Results Fat pads were sampled from 44 patients (men/women, 36:8; age, 67±13 years) with CA disease who underwent elective CA bypass grafting. Adipocyte size in ITA - PVAT and that in CA - PVAT were significantly smaller than that in SCAT . A greater extent of fibrosis and increased gene expression levels of fibrosis-related molecules were observed in CA - PVAT than those in SCAT and those in ITA - PVAT . CA - PVAT exhibited more pronounced metaflammation, as indicated by a significantly larger extent of CD 68-positive and CD 11c-positive M1 macrophages, a lower ratio of CD 206-positive M2 to CD 11c-positive M1 macrophages, a lower gene expression level of adiponectin, and higher gene expression levels of inflammatory cytokines and inflammasome- and endoplasmic reticulum stress-related molecules, than did ITA - PVAT and SCAT . Expression patterns of adipocyte developmental and pattern-forming genes were totally different among SCAT , ITA - PVAT, and CA - PVAT . Conclusions The phenotype of ITA - PVAT is closer to that of SCAT than that of CA - PVAT , which may result from inherent differences in adipocytes. ITA - PVAT appears to be protected from metaflammation and consecutive adipose tissue remodeling, which may contribute to the decreased atherosclerotic plaque burden in the ITA.Entities:
Keywords: adipokine; adipose tissue; atherosclerosis; coronary artery bypass graft; fibrosis
Mesh:
Substances:
Year: 2019 PMID: 30638109 PMCID: PMC6497339 DOI: 10.1161/JAHA.118.011147
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Primers for Human Genes in Quantitative Real‐Time PCR
| Genes | Accession No. | Forward Primer | Reverse Primer |
|---|---|---|---|
|
|
| 5′‐GTAACCCGTTGAACCCCATT‐3′ | 5′‐CCATCCAATCGGTAGTAGCG‐3′ |
|
|
| 5′‐GGCATGACCAGGAAACCAC‐3′ | 5′‐TTCACCGATGTCTCCCTTAGG‐3′ |
|
|
| 5′‐TGGATGCTCTGTACGGGAAG‐3′ | 5′‐CCAGGCTGGTGTGAAACTGAA‐3′ |
|
|
| 5′‐GCGGGAGAGTGGAAGTGAAAG‐3′ | 5′‐GTTACAAATCACAGAGACCGCT‐3′ |
|
|
| 5′‐GGGTTGCTATCACTCTCTATGC‐3′ | 5′‐TTTCTTGTCTGTTGCCGTAGTT‐3′ |
|
|
| 5′‐GGAGAACCAGGAAACGGAAAC‐3′ | 5′‐TCTCCTTCATGCGCTGCTTT‐3′ |
|
|
| 5′‐ACAGTGACGAGGTGGAGATCA‐3′ | 5′‐GATAGCGCAGTCGGTGTAGG‐3′ |
|
|
| 5′‐CGGCACTCAGCTACGCTAAC‐3′ | 5′‐CAAGTCCGGGTTGGAGTAGAC‐3′ |
|
|
| 5′‐GAGCGCAGGGCACCAAATA‐3′ | 5′‐CGAGTCAGTTTTGACCACGG‐3′ |
|
|
| 5′‐CATCACGCCGTCCTATGTCG‐3′ | 5′‐CGTCAAAGACCGTGTTCTCG‐3′ |
|
|
| 5′‐AACTCATTTTGCGGTCGCTAT‐3′ | 5′‐TCCCTGAATTGCTCGCTCAC‐3′ |
|
|
| 5′‐CACGATGCACCTGTACGATCA‐3′ | 5′‐GTTGCTCCATATCCTGTCCCT‐3′ |
|
|
| 5′‐AAATTCGGTACATCCTCGACGG‐3′ | 5′‐GGAAGGTTCAGGTTGTTTTCTGC‐3′ |
|
|
| 5′‐GACTTTAAGGGTTACCTGGGTTG‐3′ | 5′‐TCACATGCGCCTTGATGTCTG‐3′ |
|
|
| 5′‐CAGCCAGATGCAATCAATGCC‐3′ | 5′‐TGGAATCCTGAACCCACTTCT‐3′ |
|
|
| 5′‐CTGAAACACAATGCACAGAGAGA‐3′ | 5′‐AAAGATGCGAAATGTCACAACAC‐3′ |
|
|
| 5′‐GATCTTCGCTGCGATCAACAG‐3′ | 5′‐CGTGCATTATCTGAACCCCAC‐3′ |
|
|
| 5′‐CTCGATCCGCTCCTTTGATGA‐3′ | 5′‐CGTTGGTGCGGTCTATGAG‐3′ |
|
|
| 5′‐CAAGCAGAGTACACACAGCAT‐3′ | 5′‐TGCTCCACTTTTAACTTGAGCC‐3′ |
|
|
| 5′‐CTTCTGCAATTCCGACCTCGT‐3′ | 5′‐ACGCTGGTATAAGGTGGTCTG‐3′ |
|
|
| 5′‐GAGGCCAAGCCCTGGTATG‐3′ | 5′‐CGGGCCGATTGATCTCAGC‐3′ |
PCR indicates polymerase chain reaction.
Characteristics of the Recruited Patients
| Characteristics | Value |
|---|---|
| No. (men/women) | 44 (36:8) |
| Age, y | 67±13 |
| Body mass index, kg/m2 | 24.4±4.1 |
| Systolic blood pressure, mm Hg | 125±15 |
| Diastolic blood pressure, mm Hg | 72±14 |
| Pulse rate, bpm | 74±15 |
| Coronary artery disease | |
| 1‐Vessel disease | 2 (4.5) |
| 2‐Vessel disease | 13 (29.5) |
| 3‐Vessel disease | 29 (65.9) |
| Complications | |
| Diabetes mellitus | 18 (40.9) |
| Hypertension | 31 (70.5) |
| Dyslipidemia | 34 (77.3) |
| Myocardial infarction | 13 (29.5) |
| Medications | |
| Oral antidiabetic drugs | 11 (25.0) |
| Insulin | 5 (11.4) |
| ACEI or ARB | 19 (43.2) |
| β Blocker | 20 (45.5) |
| Statin | 31 (70.5) |
| Antiplatelet drugs | 38 (86.4) |
| Echocardiography | |
| Ejection fraction, % | 61±12 |
Variables are expressed as number (percentage) or mean±SD. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; bpm, beats per minute.
Laboratory Measurements
| Variable | Value |
|---|---|
| Hemoglobin, g/dL | 12.8±2.0 |
| AST, IU/L | 28 (22–36) |
| ALT, IU/L | 23 (16–38) |
| γGTP, IU/L | 27 (20–44) |
| Blood urea nitrogen, mg/dL | 17 (13–22) |
| Creatinine, mg/dL | 0.91 (0.79–1.07) |
| eGFR, mL/min per 1.73 m2 | 62.0±16.9 |
| Uric acid, g/dL | 6.2±1.4 |
| Total cholesterol, mg/dL | 159±38 |
| LDL cholesterol, mg/dL | 88±35 |
| HDL cholesterol, mg/dL | 47±11 |
| Triglycerides, mg/dL | 115 (71–137) |
| Fasting glucose, mg/dL | 100 (90–117) |
| Insulin, μU/mL | 2.3 (1.0–5.5) |
| HOMA‐R | 0.54 (0.28–1.34) |
| HbA1c, % | 6.1±0.9 |
| NT‐proBNP, pg/mL | 162 (40–277) |
Variables are expressed as mean±SD or median (interquartile range). ALT indicates alanine transaminase; AST, aspartate transaminase; eGFR, estimated glomerular filtration rate; γGTP, γ‐glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein; HOMA‐R, homeostasis model assessment of insulin resistance; LDL, low‐density lipoprotein; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Figure 1Adipocyte size in fat pads. A, Representative hematoxylin‐eosin (H‐E) staining of subcutaneous adipose tissue (SCAT) and of perivascular adipose tissue surrounding the internal thoracic artery (ITA‐PVAT) and that surrounding the coronary artery (CA‐PVAT). Bar=100 μm. B, Comparison of adipocyte sizes in SCAT, ITA‐PVAT, and CA‐PVAT (n=44 in each group). Results are shown as mean±SD. *P<0.05 vs SCAT.
Figure 2Fibrosis in fat pads. A, Representative Masson's trichrome staining of subcutaneous adipose tissue (SCAT) and of perivascular adipose tissue surrounding the internal thoracic artery (ITA‐PVAT) and that surrounding the coronary artery (CA‐PVAT). Bar=200 μm. B, Fibrosis areas in SCAT, ITA‐PVAT, and CA‐PVAT (n=19 in each group). Results are shown as mean±SD. C, Gene expression levels of fibrosis‐related molecules, including transforming growth factor‐β (TGF‐β), tissue inhibitor of metalloproteinase 1 (TIMP1), platelet‐derived growth factor subunit B (PDGFB), collagen type 6 α 1 chain (COL6a1), and macrophage‐inducible C‐type lectin (MINCLE), in SCAT, ITA‐PVAT, and CA‐PVAT (n=27 in each group). Results are shown as relative expression of each target gene in SCAT of each patient and as mean±SEM. AU indicates arbitrary unit. *P<0.05 vs SCAT; † P<0.05 vs ITA‐PVAT.
Figure 3Macrophage infiltration in fat pads. A, Representative immunohistological staining, including CD68 (a marker of macrophages), CD11c (a marker of M1 macrophages), and CD206 (a marker of M2 macrophages), of subcutaneous adipose tissue (SCAT) and of perivascular adipose tissue surrounding the internal thoracic artery (ITA‐PVAT) and that surrounding the coronary artery (CA‐PVAT). Bar=50 μm. B through D, Positive areas of immunohistological staining of CD68, CD11c, and CD206 in SCAT, ITA‐PVAT, and CA‐PVAT (n=10 in each group). E, Ratios of the macrophage infiltration areas of CD206 to CD11c in SCAT, ITA‐PVAT, and CA‐PVAT. Results are shown as mean±SD. *P<0.05 vs SCAT; † P<0.05 vs ITA‐PVAT.
Figure 4Metaflammation and adipocyte developmental and pattern‐forming factors in fat pads. A, Gene expression levels of inflammatory molecules, including monocyte chemoattractant protein‐1 (MCP‐1), interleukin‐1β (IL‐1β), interleukin‐6 (IL‐6), and tumor necrosis factor‐α (TNFα), in subcutaneous adipose tissue (SCAT) and in perivascular adipose tissue surrounding the internal thoracic artery (ITA‐PVAT) and that surrounding the coronary artery (CA‐PVAT). B, Gene expression levels of M2‐polarized state‐related molecules, including CD163, CD206, and interleukin‐10 (IL‐10), in SCAT, ITA‐PVAT, and CA‐PVAT. C, Gene expression levels of adiponectin, inflammasome‐related molecules, including nucleotide‐binding domain, leucine‐rich–containing family, pyrin domain–containing‐3 (NLRP3) and apoptosis‐associated specklike protein containing caspase recruitment domain (ASC), and endoplasmic reticulum stress‐related molecules, including glucose‐regulated protein 78 (GRP78) and C/EBP homologous protein (CHOP), in SCAT, ITA‐PVAT, and CA‐PVAT. D, Gene expression levels of adipocyte developmental and pattern‐forming factors, including engrailed homeobox 1 (EN1), empty spiracles homeobox 2 (EMX2), and homeobox A5 (HOXA5), in SCAT, ITA‐PVAT, and CA‐PVAT (n=27 in each group). Results are shown as relative expression of each target gene in SCAT of each patient and as mean±SEM. AU indicates arbitrary unit. *P<0.05 vs SCAT; † P<0.05 vs ITA‐PVAT.